Really just lately, preliminary final results from a 3rd trial evaluating ibrutinib vs . observation had been offered.105 Patients getting ibrutinib had an extended event-free of charge survival, but no All round survival advantage, Even though the final results had been even now immature. Also, Though serious adverse functions fees were being equi